Status:
UNKNOWN
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
Lead Sponsor:
Institut Paoli-Calmettes
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Chronic Lymphocytic Leukemia (CLL) is still an incurable disease. However recent advances have established correlation between the quality of the response (in particular achievement of negativity of m...
Detailed Description
Objective(s) of the clinical study Main objective: \- To improve the minimal residual disease (MRD) negative complete response (CR) rate after consolidation using subcutaneous low dose of rituximab ...
Eligibility Criteria
Inclusion
- CLL (Matutes 4 or 5) in CR after induction treatment with negative MRD or PR
- age\>18
- performance status\<=2
- signed informed consent
Exclusion
- cytopenia
- other malignant affection
- HIV or HBV positive
- steroids treatment
- richter syndrome
- pregnant or breastfeeding women
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2015
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01521689
Start Date
December 1 2011
End Date
June 1 2015
Last Update
March 20 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Paoli Calmettes
Marseille, France, 13009